Fraczek Marcin, Woźniak Zdzisław, Ramsey David, Zatoński Tomasz, Nadolska Beata, Krecicki Tomasz
Klinika Otolaryngologii Akademii Medycznej we Wrocławiu.
Otolaryngol Pol. 2007;61(5):668-74. doi: 10.1016/S0030-6657(07)70504-8.
CDC25 phosphatases, significant positive regulators of the cell cycle play a pivotal role in controlling cell proliferation during development and tumorigenesis. The prevalence and clinical implications of CDC25 immunoreactivity in laryngeal squamous cell cancer (LSCC) patients however, have not been elucidated.
The object of the study was to assess the relationship between the expression levels of CDC25A, CDC25B and clinicopathological parameters and overall survival time of patients with LSCC.
Tissue blocks from 46 patients treated surgically at our institution between 1992 and 2000 were available for this study. Immunohistochemistry using polyclonal antibodies against CDC25A and CDC25B was used to examine proteins expression. Ki-67 antigen expression was examined as a cell proliferation marker. Control group consisted of 21 samples of unchanged mucosa.
CDC25A and CDC25B expression was observed in 96% (44/46) and 56.5% (26/46) of tumors; the mean labeling index was 73.9% and 36.5% respectively. CDC25 phosphatases expression was higher in LSCC compare to the control group (p<0.001). There was not any significant correlation between the levels of CDC25 phosphatases and investigated variables. In univariate analysis, all classical clinicopathological parameters but none of the proteins were related to the overall survival time.
The expression of CDC25A, CDC25B and the proliferation marker Ki-67 are not associated with prognosis in LSCC.
